2018
Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability.
Raj N, Shah R, Stadler Z, Mukherjee S, Chou J, Untch B, Li J, Kelly V, Saltz L, Mandelker D, Ladanyi M, Berger M, Klimstra D, Reidy-Lagunes D, Osoba M. Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability. JCO Precision Oncology 2018, 2018: 1-18. PMID: 30687805, PMCID: PMC6345401, DOI: 10.1200/po.17.00267.Peer-Reviewed Original ResearchMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer TargetsNext-generation sequencingPancreatic neuroendocrine tumorsGermline genetic analysisLoss of heterozygosityMetastatic PanNETsNeuroendocrine tumorsHigh-penetrance cancer susceptibility genesPresence of loss of heterozygosityAdvanced pancreatic neuroendocrine tumorsMetastatic pancreatic neuroendocrine tumorsGenetic analysisSomatic loss of heterozygosityInferior overall survivalCancer susceptibility genesIncreasing tumor gradeTarget of rapamycin pathway genesRoutine clinical practice settingClonal evolution patternsMammalian target of rapamycin pathway genesChromatin remodeling factorsReal-time molecular profilingFrequent somatic mutationsClinical practice settingSequence of pre-
2017
Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor
Gerson JN, Witteles RM, Chang DT, Beygui RE, Iagaru AH, Kunz PL. Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor. Pancreas 2017, 46: 1381-1385. PMID: 29040196, DOI: 10.1097/mpa.0000000000000932.Peer-Reviewed Original ResearchConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsCarcinoid syndromeRight upper quadrant abdominal painUpper quadrant abdominal painMetastatic pancreatic neuroendocrine tumorsRight-sided heart diseaseQuadrant abdominal painPulmonic valve replacementAbdominal painSystemic chemotherapyTreatable complicationHormone excessSerum serotoninValve replacementHeart diseaseHeterogeneous groupSyndromeElevated levelsTumorsDiseaseImportant entityDyspneaEmesisPain
2015
Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).
Kulke M, Niedzwiecki D, Foster N, Fruth B, Kunz P, Kennecke H, Wolin E, Venook A. Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). Journal Of Clinical Oncology 2015, 33: 4005-4005. DOI: 10.1200/jco.2015.33.15_suppl.4005.Peer-Reviewed Original ResearchPancreatic neuroendocrine tumorsRandomized phase II studyMetastatic pancreatic neuroendocrine tumorsPhase II studyII studyNeuroendocrine tumorsEverolimusBevacizumabPatientsTumors
2012
PDX-1, CDX-2, TTF-1, and CK7
Chan ES, Alexander J, Swanson PE, Jain D, Yeh MM. PDX-1, CDX-2, TTF-1, and CK7. The American Journal Of Surgical Pathology 2012, 36: 737-743. PMID: 22498824, DOI: 10.1097/pas.0b013e31824aba59.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCDX2 Transcription FactorDiagnosis, DifferentialDNA-Binding ProteinsFemaleHomeodomain ProteinsHumansImmunohistochemistryIntestinal NeoplasmsKeratin-20Keratin-7Liver NeoplasmsLung NeoplasmsMaleMiddle AgedNeuroendocrine TumorsPancreatic NeoplasmsSensitivity and SpecificitySingle-Blind MethodTrans-ActivatorsTranscription FactorsConceptsGI neuroendocrine tumorsThyroid transcription factor-1Pancreatic neuroendocrine tumorsBronchopulmonary neuroendocrine tumorsMetastatic neuroendocrine tumorsPrimary neuroendocrine tumorNeuroendocrine tumorsCDX-2PDX-1Primary siteMetastatic pancreatic neuroendocrine tumorsPrimary pancreatic neuroendocrine tumorsDuodenal neuroendocrine tumorsΒ-cell functionSimilar morphologic featuresPancreatic duodenal homeobox-1Good overall diagnostic accuracyOverall diagnostic accuracyDuodenal homeobox 1Radiologic dataTranscription factor 1IHC panelImmunohistochemical markersIHC analysisKeratin 7
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply